Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3113 studies found for:    "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Completed
Has Results
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: tositumomab and iodine I-131 tositumomab
22 Unknown  Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
23 Completed
Has Results
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.
24 Active, not recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (CHRONOS-1)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
25 Completed
Has Results
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
26 Suspended BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
27 Completed
Has Results
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
28 Completed
Has Results
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
29 Completed Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody
30 Completed
Has Results
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
31 Completed
Has Results
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
32 Completed
Has Results
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
33 Completed Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: GSK461364
34 Terminated
Has Results
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Bexxar (tositumomab);   Procedure: External beam radiotherapy (XRT);   Drug: Potassium Iodide (KI)
35 Active, not recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
36 Completed
Has Results
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen
37 Completed Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab
Condition: Lymphoma, Non-Hodgkin
Intervention:
38 Completed Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab
Condition: Lymphoma, Non-Hodgkin
Intervention:
39 Completed Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Tositumomab 450 mg;   Drug: Tositumomab 35 mg
40 Completed Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Procedure: PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.